Invivo Partners

Invivo Partners is a venture capital firm based in Barcelona, Spain, specializing in early-stage investments in the life sciences sector. The firm focuses on biotechnology, medical devices, and e-Health companies, aiming to support innovative projects that have the potential to transform healthcare. Invivo Partners manages three funds, including Invivo Ventures III, which targets €100 million for investments in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. The firm has a majority of private investors, with support from institutional investors such as the European Investment Fund (EIF), Fond-ICO Next Tech, the Catalan Finance Institute, and the Barcelona City Council. Invivo Partners has invested in 15 companies and has achieved three successful exits. Their portfolio companies have raised over €350 million from global venture capital firms. The firm's team combines scientific, technical, and financial expertise to make impactful investments and foster growth in the health sector. With a deep understanding of technology transfer and market trends, Invivo Partners aims to become a leading player in Europe's biotech industry. Invivo Partners is managed by Luis Pareras, Albert Ferrer, and Laura Rodríguez, who bring complementary experience in science, technology transfer, and entrepreneurship to the firm. The team is committed to identifying and supporting innovative companies that can make a significant impact on healthcare and society. Invivo Partners' approach is characterized by a hands-on investment strategy, providing not only capital but also strategic guidance to help portfolio companies scale and succeed in the competitive life sciences market. The firm's focus on early-stage investments allows them to support companies from the ground up, nurturing their growth and development to reach their full potential. Invivo Partners' commitment to innovation and excellence has established them as a respected and influential entity in the European venture capital landscape, particularly within the life sciences sector. Their ongoing efforts continue to drive advancements in healthcare, contributing to the evolution of medical treatments and technologies that improve patient outcomes and quality of life.